Editor's letter

Welcome to the latest issue of Pharmaceutical Technology Focus magazine

The growing global demand for cell and gene therapies (CGTs) is resulting in a manufacturing paradigm shift, reflecting the need to overcome a range of evolving new challenges and adapt to maintain rigorous safety and efficacy standards.

This month’s cover story looks at how the acceleration in CGT approvals in recent years not only highlights the potential of these therapies, but also underscores the growing demand for specialised and expanded manufacturing capabilities.

Also in this issue, a feature examines what lessons researchers can take from the Covid-19 pandemic to address the growing mpox public health emergency. Ten years after Bristol Myers Squibb’s (BMS) Opdivo, Merck & Co’s Keytruda were approved, they continue to be major revenue drivers for the respective companies. An opinion piece assesses the market entry strategies, pricing dynamics over time of both drugs. All this, along with the latest news and deals in the pharmaceutical landscape.

Ross Law, deputy editor